Skip to main content

Table 1 Participant characteristics for the entire aneurysmal subarachnoid hemorrhage cohort and discovery and replication sample subsets

From: Iron homeostasis pathway DNA methylation trajectories reveal a role for STEAP3 metalloreductase in patient outcomes after aneurysmal subarachnoid hemorrhage

Variable

aSAH cohort (n = 648)

Discovery sample (n = 260)

Replication sample (n = 100)

Age, mean years (SD)

53.2 (11.5)

53.1 (11.0)

54.2 (12.0)

Sex, female, n (%)

469 (72.4)

179 (68.8)

76 (76.0)

Self-identified race, white, n (%)

563 (86.9)

225 (86.5)

91 (91.0)

Treatment, coil embolization, n (%)

402 (62.0)

159 (61.2)

66 (66.0)

Fisher grade, n (%)

   

 2

266 (41.0)

78 (30.0)

41 (41.0)

 3

279 (43.1)

126 (48.5)

43 (43.0)

 4

103 (15.9)

56 (21.5)

16 (16.0)

Outcome

N

Unfavorable, n (%)

N

Unfavorable, n (%)

N

Unfavorable, n (%)

CV

396

206 (52.0)

168

91 (54.2)

NAa

DCI

631

253 (40.1)

258

127 (49.2)

GOS-3

555

149 (26.8)

214

71 (33.2)

99

38 (38.4)

GOS-12

530

121 (22.8)

204

53 (26.0)

93

29 (31.2)

Death-3

594

88 (14.8)

232

39 (16.8)

99

24 (24.2)

Death-12

530

96 (18.1)

204

44 (21.6)

93

26 (28.0)

  1. aSAH, aneurysmal subarachnoid hemorrhage; SD, standard deviation; CV, cerebral vasospasm (unfavorable = CV present); DCI, delayed cerebral ischemia (unfavorable = DCI present); GOS-3, Glasgow Outcome Scale at 3 months (unfavorable = 1–3); GOS-12, Glasgow Outcome Scale at 12 months (unfavorable = 1–3); Death-3, death at 3 months (unfavorable = yes); Death-12, death at 12 months (unfavorable = yes); aCV and DCI were not examined in the replication sample given null association in discovery analyses